Inhibiting Ferroptosis Prevents the Progression of Steatotic Liver Disease in Obese Mice

Inhibiting Ferroptosis Prevents the Progression of Steatotic Liver Disease in Obese Mice

Ferroptosis, a form of regulated cell death characterized by lipid peroxidation and iron accumulation, has been implicated in the progression of metabolic-dysfunction-associated steatohepatitis (MASH) in obesity. This study investigated the role of ferroptosis in the development of hepatic steatosis...

Full description

Saved in:

Bibliographic Details
Main Authors:	Gi Cheol Park, Soo-Young Bang, Ji Min Kim, Sung-Chan Shin, Yong-il Cheon, Kwang Min Kim, Hanaro Park, Eui-Suk Sung, Minhyung Lee, Jin-Choon Lee, Byung-Joo Lee
Format:	Article
Language:	English
Published:	MDPI AG 2024-10-01
Series:	Antioxidants
Subjects:	obesity ferroptosis metabolic-dysfunction-associated steatotic liver disease (MASLD) hepatic steatosis iron metabolism
Online Access:	https://www.mdpi.com/2076-3921/13/11/1336
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Correspondence to letter to the editor 1 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
by: Seogsong Jeong, et al.
Published: (2025-04-01)

Applicability of Statins in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Thaninee Prasoppokakorn
Published: (2025-01-01)

From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome – current insights and future directions
by: Bruno Basil, et al.
Published: (2024-12-01)

Prevalence of metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease patients: an Egyptian cross-sectional study
by: Shimaa Y. kamel, et al.
Published: (2025-06-01)

Consecutive fecal microbiota transplantation for metabolic dysfunction-associated steatotic liver disease: a randomized controlled trial
by: Bas Groenewegen, et al.
Published: (2025-12-01)

Association of platelet to albumin ratio with metabolic dysfunction-associated steatotic liver disease based on the National Health and Nutrition Survey 2017–2018
by: Jiao Xie, et al.
Published: (2025-03-01)

Predictive factors for metabolic syndrome in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
by: Mohammad Alnees, et al.
Published: (2025-08-01)

Consensus Statement on Metabolic Dysfunction‐Associated Steatotic Liver Disease in Children and Adolescents From the Joint TASL‐TSPGHAN Expert Committee
by: Yu‐Cheng Lin, et al.
Published: (2025-06-01)

Unraveling the link between metabolic dysfunction-associated steatotic liver disease and osteoporosis: a bridging function of gut microbiota
by: Jing Zhang, et al.
Published: (2025-04-01)

Effect of treadmill walking on cardiometabolic risk factors and liver function markers in older adults with MASLD: a randomized controlled trial
by: Jiyoun Kim, et al.
Published: (2025-04-01)

Perirenal fat thickness is an independent predictor for metabolic syndrome in steatotic liver disease
by: Jong Wook Choi, et al.
Published: (2024-11-01)

Increased serum uric acid to creatinine ratio is associated with metabolic dysfunction associated steatotic liver disease
by: Fang Wang, et al.
Published: (2025-07-01)

Association of metabolic dysfunction-associated steatotic liver disease and steatosis-associated fibrosis estimator with subclinical coronary atherosclerosis: observation cohort study
by: Joonho Jeong, et al.
Published: (2025-07-01)

The correlation between heavy metal ions in blood and metabolic dysfunction-associated steatotic liver disease from 1999 to 2018 based on NHANES data
by: Haijun Ma, et al.
Published: (2025-01-01)

Post-translational modifications in the pathophysiological process of metabolic dysfunction‑associated steatotic liver disease
by: Yiyang Min, et al.
Published: (2025-06-01)

Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma
by: Toru Nakamura, et al.
Published: (2025-03-01)

Quercetin: A Promising Candidate for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Julia Markowska, et al.
Published: (2024-11-01)

Evolution of characteristics of MASLD with and without diabetes: a meta-analysis of placebo arms
by: Han Ah Lee, et al.
Published: (2024-11-01)

Phocaeicola dorei ameliorates progression of steatotic liver disease by regulating bile acid, lipid, inflammation and proliferation
by: Jieun Choi, et al.
Published: (2025-12-01)

Attenuation Based Quantitative Evaluation of Hepatic Steatosis Using US: Current Status and Future Perspective
by: Dong Ho Lee
Published: (2025-05-01)

Causal association of cholesterol metabolism-related proteins with hepatocellular carcinoma and dysfunction-associated steatotic liver disease: a mendelian randomization study
by: Dianzhe Tian, et al.
Published: (2025-06-01)

Clinical characteristics of MASLD/MetALD/MAFLD/NAFLD and the relative risk analysis on metabolic disorders
by: Hong-ye Peng, et al.
Published: (2025-05-01)

Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease
by: Hye Won Lee, et al.
Published: (2025-07-01)

PI3K/AKT signaling pathway plays an important role in the pathogenesis of metabolic dysfunction-associated steatotic liver disease
by: Cuiping Shao, et al.
Published: (2025-07-01)

Impact of shear wave elastography and attenuation imaging for predicting life-threatening event in patients with metabolic dysfunction-associated steatotic liver disease
by: Yudai Fujiwara, et al.
Published: (2025-02-01)

A social media listening study of patients’ experiences relating to metabolic dysfunction-associated steatotic liver disease: The LISTEN-MASLD study
by: Jeffrey V. Lazarus, et al.
Published: (2025-01-01)

Diagnostic performance of FibroTouch® in assessing hepatic steatosis and fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: An Asian experience
by: Thanikan Sukaram, et al.
Published: (2025-01-01)

A prospective study on the role of non-invasive tests in the evaluation of diabetes mellitus associated steatotic liver disease
by: Zülal İstemihan, et al.
Published: (2025-07-01)

Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Emerging Pathogenic Mechanisms and Therapeutic Implications
by: Farah Abdelhameed, et al.
Published: (2025-03-01)

Cholesterol and the gut-liver axis: unraveling their role in the onset and progression of metabolic-associated steatotic liver disease
by: Luis A. Rodríguez-Rojas, et al.
Published: (2025-08-01)

MIND diet score and its association with metabolic dysfunction-associated steatotic liver disease and gut microbiota profiles: a cross-sectional study
by: Shengbo Yang, et al.
Published: (2025-08-01)

Molecular spectroscopy of blood plasma differentiates metabolic dysfunction-associated steatohepatitis from steatosis
by: Barbora Nováková, et al.
Published: (2025-08-01)

Association between circadian syndrome and MASLD risk: evidence from a large cross-sectional study
by: Jihan Sun, et al.
Published: (2025-05-01)

Epidemiological trends and burden of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa region: a 32-year analysis of health impact
by: Zahra Sarkoohi, et al.
Published: (2025-06-01)

Nonlinear association between body roundness index and metabolic dysfunction associated steatotic liver disease in nondiabetic Japanese adults
by: Cheng Huang, et al.
Published: (2025-05-01)

Development of SOCS1 mimetics as novel approach to harmonize inflammation, oxidative stress, and fibrogenesis in metabolic dysfunction-associated steatotic liver disease
by: Susana Bernal, et al.
Published: (2025-07-01)

Association between cholecystectomy and the risk of new-onset metabolic dysfunction-associated steatotic liver disease: a risk-stratified cohort study
by: Hong Jae Jeon, et al.
Published: (2025-08-01)

Weight gain in infancy and metabolic dysfunction-associated steatotic liver disease (MASLD) in a prospective birth cohort of Latino children
by: Sarah L. Maxwell, et al.
Published: (2025-08-01)

<i>Lactobacillus</i> sp. for the Attenuation of Metabolic Dysfunction-Associated Steatotic Liver Disease in Mice
by: Titilayo Olotu, et al.
Published: (2024-12-01)

Association between long-term exposure to ambient air pollution and an increased risk of steatotic liver disease
by: Su Hwan Cho, et al.
Published: (2025-07-01)